Role of Hyperpolarized 13C-Pyruvate MR Spectroscopy in Patients With Intracranial Metastasis Treated With (SRS)

Upwards of 40% of cancer patients will develop brain metastases during their illness, most of which become symptomatic. The burden of brain metastases impacts the quality and length of survival. Thus the management of brain metastases is a significant health care problem. Standard treatment options include stereotactic radiosurgery and/or whole brain radiation. There is a great interest in studying the association between the functional characteristics of tumors - such as tumour hypoxia and lactate accumulation - and clinical outcomes in order to guide management. These characteristics may pre

Trial Details

NCT ID

NCT03324360

Phase

PHASE1

Sponsor

Sunnybrook Health Sciences Centre

Status

RECRUITING

Cancer Type

Brain Cancer

Interventions

• Hyperpolarized 13C-Pyruvate

Locations (sample)

• Toronto, Ontario, Canada|43.70643,-79.39864

Key Eligibility Criteria

• Part I (Controls) Group A
• Participants of all ethnic groups/race categories (≥18yrs old)
• Informed consent Group B
• Male participants of all ethnic groups/race categories (between the age of 18-39)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Brain Cancer Trials on Trialify →